Initiation and Monitoring of Finerenone in Adults with Type 2 Diabetes and Chronic Kidney Disease
Eligibility Criteria
- Finerenone should be added to a maximally tolerated ACE inhibitor or ARB in adults with type 2 diabetes and CKD who have an estimated GFR ≥ 25 mL/min/1.73 m², albumin‑to‑creatinine ratio ≥ 30 mg/g, and serum potassium ≤ 4.8–5.0 mmol/L before the first dose. 1
- All three criteria (eGFR ≥ 25 mL/min/1.73 m², UACR ≥ 30 mg/g, potassium ≤ 5.0 mmol/L) must be met simultaneously; finerenone is never used as monotherapy or as a replacement for ACEi/ARB therapy. 1
Baseline Therapy Requirements
- Patients must have been on a stable, maximally tolerated dose of an ACE inhibitor or ARB for at least one month prior to adding finerenone. 1
Dosing Algorithm According to Baseline eGFR
| Baseline eGFR (mL/min/1.73 m²) | Recommended Initial Dose of Finerenone |
|---|---|
| > 60 | 20 mg once daily |
| 25 – 60 | 10 mg once daily |
| < 25* | Do not initiate (continue only if already on therapy) |
Monitoring Protocol
- Baseline: Verify serum potassium ≤ 4.8–5.0 mmol/L, document eGFR and UACR ≥ 30 mg/g. 1
- 4 weeks after initiation: Mandatory serum potassium measurement. 1
- 4 weeks after any dose adjustment: Mandatory serum potassium measurement. 1
- Ongoing: Regular serum potassium monitoring throughout therapy; periodic eGFR checks. Finerenone may be continued even if eGFR falls below 25 mL/min/1.73 m² provided potassium stays controlled. 1
Dose Adjustment Based on Serum Potassium
- Potassium < 4.8 mmol/L: Titrate dose from 10 mg to 20 mg once daily. 1
- Potassium ≤ 5.5 mmol/L: Maintain current dose. 1
- Potassium > 5.5 mmol/L: Discontinue finerenone; once potassium ≤ 5.0 mmol/L, restart at 10 mg once daily. 1
Contra‑indications and Common Errors to Avoid
- Do not use finerenone as monotherapy; it must always be combined with an ACE inhibitor or ARB. 1
- Do not combine finerenone with other mineralocorticoid receptor antagonists (e.g., spironolactone, eplerenone). 1
- Do not omit the 4‑week serum potassium check after initiation or any dose change. 1
- Do not automatically stop finerenone solely because eGFR falls below 25 mL/min/1.73 m² if potassium remains within target. 1
Position Within Comprehensive Cardiorenal Care (KDIGO 2022)
- KDIGO 2022 recommends that adults with type 2 diabetes and CKD receive an ACE inhibitor or ARB as first‑line therapy, followed by an SGLT2 inhibitor when eGFR ≥ 20 mL/min/1.73 m²; finerenone is added as an additional agent for patients who meet the eligibility criteria. 2